PMH39 Which Adverse Effects Influence the Dropout Rate in Selective Serotonin Reuptake Inhibitor (Ssri) Treatment?  by Kostev, K. et al.
A460  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
in terms of longer length of stay, more readmissions and higher consumption of 
drugs. The average quality of the studies was moderate. Further research is needed 
to establish the degree of burden of agitation and containment borne by hospitals 
and the health care system.
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Objectives: Nowadays selective serotonin reuptake inhibitors (SSRIs) are the most 
frequently prescribed antidepressants due to their better clinical efficacy, effec-
tiveness, tolerability, and safety, when compared to tricyclic antidepressants or 
monoamino oxidase inhibitors. However, despite this, especially at the beginning 
of treatment SSRIs are associated with side effects, which may lead to premature 
discontinuation of therapy in some cases. Assessment of these factors was the aim 
of the present study. MethOds: This retrospective database analysis used data 
from 50,824 patients first time treated with SSRIs for major depressive disorder 
selected from a Electronic Medical Records (EMR) database (IMS Disease Analyzer) 
in Germany, providing information on SSRI side effects and their influence on pre-
mature treatment discontinuation calculated by regression analysis. In addition to 
that, presence of certain co-morbidities was registered. Results: Mean age was 
54.5 ± 19 years with two-thirds of study population being female. Most frequently 
mentioned adverse effects were “discomfort” of the digestive system (10%), sleep 
disorders (8.6%), and heart rhythm disorders (4%); however, these were of tolerable 
severity as they did not significantly influence dropout rate. Contrary to that, espe-
cially somnolence and younger age (≤ 50 years) increased the chance of premature 
treatment discontinuation, while patients suffering from cardiovascular risk factors 
or osteoporosis tended to adhere to therapy. cOnclusiOns: Overall, the findings 
indicate a good tolerability of SSRIs at the beginning of treatment, whereas occur-
rence of somnolence leads to incompliance.
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Objectives: The aim of this study to explore patients’ general and specific beliefs 
about medicines among depressed patients and effect on adherence MethOds: 
A cross-sectional design used to measure patients’ general and specific beliefs 
among depressed patients, using BMQ general and specific scale. Patients were 
recruit from outpatient clinic at AL-Amal hospital in Riyadh (psychiatric hospital) 
between 2013 and January 2014. Results: A total of 403 patients meet the inclu-
sion criteria and were participated in this study. Two hundred three representing 
50.37 % of the total study sample, were female, while the remaining 200 (49.6 %) 
were male, with average 39 years. Half of the patients (52.9%) report low adherence 
to antidepressant medication. Both low and high adherence group scored high in 
the necessity beliefs (18.02 (SD 3.91) -18.32 (SD 3.9) respectively with no statistically 
different. contrariwise patients with high adherence had significantly lower level of 
concerns belief about antidepressants medication and less harmful belief also the 
same finding with general overuse belief. cOnclusiOns: General patients beliefs 
either general overuse or general harm about medication influence patients taking 
medication behavior and have negative correlation with adherence to medication 
on another hand only specific concerns belief to antidepressant have a positive 
correlation with adherence to antidepressant this finding will help psychiatric to 
improve adherence and clinical outcome by addressing medications taking behavior 
using a systematic approach based in this finding.
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Objectives: Patients adherence studies are essential for evaluating the quality of 
care delivery of a health facility and patients’ role in improving their conditions. 
The objective of this study is to determine the level of adherence of outpatients to 
psychotropic drugs and evaluate the impacting factors. MethOds: The study was 
a cross-sectional study done at the psychiatric hospital, Uselu, Benin city, Nigeria 
from April to September, 2013. Convenient sampling method was used in popula-
tion size determination for data collection. The participants were adult patients (18 
years and above) attending the outpatients psychiatric clinic of the hospital with 
diagnosis of various psychiatric illnesses. A total of 250 patients participated in the 
study and a well-structured self-report 10-item questionnaire using the medica-
tion adherence rating scale (MARS) was used. Additional information was patients’ 
socio-demographic profile and clinical variables that affect patients’ adherence to 
medications. Adherence to medication data were analyzed with respect to gender 
and level of adherence and factors that impact patients’ adherence. Results: The 
level of patients’ adherence to psychotropic was 63.6% and factors found to signifi-
cantly affect adherence include amount spent per clinic visit, perception of social 
support, intake of alcohol, medication side effects, and existing denial of illness and 
use of traditional medicine. cOnclusiOns: The level of adherence to psychotropic 
medications was fairly high and factors that were significantly related to adherent 
status were amount spent per clinic visit, perception of social support, intake of 
alcohol, medication side effects, existing denial of illness and use of traditional 
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Objectives: The purpose of the present study is to conduct an economic evaluation 
of Agomelatine vs the current alternatives in daily clinical practice for treating patients 
with major depression disorders (MDD) in Italy (Venlafaxine, Fluoxetine, Sertraline, 
Escitalopram and Duloxetine). MethOds: Using a Markov model-based cost-effec-
tiveness analysis, Agomelatine was compared with other therapies used for the treat-
ment of MDD commonly prescribed (Venlafaxine, Fluoxetine, Sertraline, Escitalopram 
and Duloxetine), chosen on the basis of market shares, and compared with placebo. 
The population considered in the model consists of patients suffering from MDD 
and with an average age of 45 years. The perspective of the third party payer (Italian 
National Healthcare Service) and the societal perspective were considered. Results: 
The study shows that Agomelatine administration is linked with higher direct and 
indirect costs only when compared with Duloxetine (respectively € 4,365 vs. € 4,253 
and € 5,553 vs. € 5,484). Nevertheless, Agomelatine has the higher efficacy in terms 
of QALY gained (1.477) in comparison to all comparators considered in the analysis. 
According to the societal perspective, Agomelatine is dominant against Venlafaxine, 
Escitalopram, Fluoxetine and Sertraline, since it is less expensive and more effective 
and cost-effective compared to Duloxetine since the incremental cost per QALY gained 
is € 12,461. According to the perspective of the Italian NHS, Agomelatine is dominant 
versus Venlafaxine, Fluoxetine and Sertraline and is cost-effective in comparison to 
Duloxetine (ICER 6,101 € /QALY) and Escitalopram (3,336 € /QALY). cOnclusiOns: 
The present economic evaluation indicates that Agomelatine provides greater ben-
efit and is less costly compared to generic Venlafaxine, generic Escitalopram, generic 
Fluoxetine and generic Sertraline and that Agomelatine is cost-effective compared to 
Duloxetine. In conclusion, according to its favorable tolerability profile and its proven 
efficacy, Agomelatine represents a powerful tool for many patients suffering from 
MDD, which may lead to both clinical and economic advantages.
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Objectives: The Swedish national payer, TLV, was interested in understanding how 
OLAI is used in routine clinical practice regarding dosing and its impact on psychiat-
ric-related hospitalization. MethOds: Three Swedish nationwide health registers: 
the patient register, the drug register and the mortality register were linked. Patients 
with ≥ 1 prescription of OLAI and one diagnosis of schizophrenia or schizoaffective 
disorder prior to initiation of OLAI were included in this retrospective patient mirror-
image study. The minimum follow-up was six months. The study period was from 
03/2010 until 12/2011. The average number and duration of hospitalizations were 
compared before and after initiation with OLAI using a Student’s t-test. Results: 
70 patients met the inclusion criteria. The proportion of patients being hospitalized 
≥ 1 was 77% in the pre-index period and 67% in the post-index period. The number of 
outpatient visits increased from 45% prior to OLAI to 77% post initiation. The results 
showed a significant reduction in the mean length of stay per hospitalization (19.6 
days vs 3.9 days [p< 0.001] ), and in the mean total number of days spent in hospital 
per patient (52.3 days vs. 16.2 days [p< 0.001] ). No significant difference was seen in 
the number of hospital visits between the pre- and post-initiation periods, although 
there was a numerical decrease observed within the post-index period. The average 
dose of OLAI was 18.1 mg per day (95% CI: 16.6 mg; 19.7 mg) and the prescription 
refill period was 19.6 days (95% CI: 17.7 days; 21.5 days). cOnclusiOns: This study 
provides evidence that initiation with OLAI significantly reduces the length of stay 
per hospitalization and the total days spent in hospital.
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Objectives: The aim of this study was to evaluate the use of services and costs 
related to agitation and containment of adult patients admitted to a psychiatric 
hospital. MethOds: Systematic review through searches of Pubmed, CINHAL and 
Web of Knowledge (using a wide variety of terms related to agitation; inpatient care 
and use of services/costs); bibliographic references in retrieved studies and expert 
consultation. Studies published since 1998 were selected in duplicate by review-
ing abstracts and full-text papers. Results: After removing duplicates, 372 papers 
were reviewed and 11 included in the review. Four studies were of high quality, 4 
of moderate-high to moderate-low quality and three of low quality. Eight of the 
studies evaluated the impact of agitation on the length of stay and 6 showed that 
it was associated with longer stays. Four studies evaluated the impact of agitation 
on readmission and showed a statistically significant increase in the probability of 
readmission of agitated patients in comparison with non-agitated patients. Two 
studies evaluated medication, one showed that the mean medication dose was 
higher in agitated patients and the other found higher costs of treatment com-
pared with non-agitated patients in the unadjusted analysis. Another estimated 
the costs of conflict and containment related to acute inpatient psychiatric care 
in UK. The total annual cost in England for all conflict was £72.55 million (£145,177 
annual conflict cost per ward) and £106 million for containment (£212,316 annual 
containment cost per ward). cOnclusiOns: Studies on use of services and costs 
of agitation are scarce. Overall, agitation has an effect on health care use and costs 
